$ORMP News

Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company

Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company

Oramed Pharma Receives $18M Payment From Scilex Holdings, Representing $118M Total Returns On $99.5M Investment; Oramed Retains $39M Outstanding debt, Convertible Debt, Warrants, and Ongoing Royalty Interest

Oramed Pharmaceuticals: Scarred, Well-Capitalized, And Regrouping After Setback

There Are Some Holes In Oramed Pharmaceuticals' (NASDAQ:ORMP) Solid Earnings Release

ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS

Reported November 13, 2025: Oramed Pharmaceuticals Q3 EPS $1.26 Beats $(0.08) Estimate, Sales $2.000M

Oramed: Q3 Earnings Snapshot

The past three years for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitable

Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives

Oramed Advances Oral Insulin Program Independently; Announces Launch Of New U.S. Trial; Company Reaffirms Commitment To Rewarding Shareholders, Including Plans For One-Time Dividend

Oramed Advances Oral Insulin Program Independently; Announces Launch Of New U.S. Trial; Company Reaffirms Commitment To Rewarding Shareholders, Including Plans For One-Time Dividend

Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant Repurchase

Oramed: Q2 Earnings Snapshot

Oramed Grants Scilex $27M Option To Repurchase Warrants, With Potential Note Extension To 2026

We're Not Very Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Rate

Oramed Pharmaceuticals Extends Stock Buyback Program For One Year

The past three years for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitable

Oramed: Q1 Earnings Snapshot

Oramed Pharma Closes Strategic Investment In Alpha Tau Medical; Oramed Affiliate Purchases About 14.1M Alpha Tau's Ordinary Shares $2.612/Shr